Skip to main content

Advertisement

SpringerLink
Log in

Impact and Assessment of Sleep Disturbance in Adults and Children with Allergic Rhinitis

  • Allergic Rhinitis (J Maspero, Section Editor)
  • Published:
Current Treatment Options in Allergy Aims and scope Submit manuscript

Abstract

Purpose of Review

In this article, we review the impact and the treatment of sleep disturbance caused by allergic rhinitis (AR) in adult and pediatric patients.

Recent Findings

Although intranasal corticosteroids (INS) remain the mainstay treatments for AR-induced sleep disturbance, allergen immunotherapy (AIT) has been suggested to be effective in altering the course and progression of moderate-to-severe AR that is refractory to pharmacotherapy. MP-AzeFlu is a recently developed formulation containing azelastine, an intranasal antihistamine (INAH), and fluticasone propionate, an INS. MP-AzeFlu has been reported to have a fast onset of action thanks to the effect of the INAH.

Summary

AR is one of the most common chronic inflammatory diseases in the USA with symptoms that can severely affect patients’ quality of life. Sleep disturbance is a serious consequence of AR-induced symptoms that can lead to daytime somnolence, impaired cognitive functions, and decreased work/school performance. Nasal congestion and rhinorrhea have been suggested to be the primary causes of sleep disturbance in patients with AR. There is a lack of adequate assessment method for AR-induced sleep disturbance and its consequences in the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines and the Sino-Nasal Outcome Test-22 (SNOT-22). The NIH-developed Patient Reported Outcome Measurement Information System (PROMIS) has measures for these symptoms. Although more research is needed to develop more pediatric-specific questionnaires, PROMIS is a good start. In terms of treatment for AR-induced sleep disturbance, therapy should be aimed at treating the nasal congestion and rhinorrhea caused by AR. INS are the mainstay treatments for moderate-to-severe AR. The newer INS have low systemic bioavailability and are well tolerated. For adults, fluticasone propionate is an effective treatment. For children from 2 to 4 years old, mometasone and fluticasone furoate are recommended. Fluticasone propionate should be used in children age 4 or older. Budesonide is the only category B safety drug as classified by the FDA, making it recommended treatment for pregnant and breastfeeding women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. •• Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–8. https://doi.org/10.1016/j.jaci.2017.03.050. This article provides detailed guidelines for the classfications of allergic rhinitis and evidence-based recommendations for each classification

    Article  PubMed  Google Scholar 

  2. •• Sur DKC, Plesa ML. Treatment of allergic rhinitis. Am Fam Physician. 2015;92(11):985–92. This article provides a thorough description of the different treatments for allergic rhinitis

    PubMed  Google Scholar 

  3. •• Scadding GK. Optimal management of allergic rhinitis. Arch Dis Child. 2015;100(6):576–82. https://doi.org/10.1136/archdischild-2014-306300. This article provides a thorough description of the classifications of allergic rhinitis as well as its current treatments

    Article  PubMed  PubMed Central  Google Scholar 

  4. Berger WE, Meltzer EO. Intranasal spray medications for maintenance therapy of allergic rhinitis. Am J Rhinol Allergy. 2015;29(4):273–82. https://doi.org/10.2500/ajra.2015.29.4215.

    Article  PubMed  Google Scholar 

  5. Varshney J, Varshney H. Allergic rhinitis: an overview. Indian J Otolaryngol Head Neck Surg. 2015;67(2):143–9. https://doi.org/10.1007/s12070-015-0828-5.

    Article  PubMed  PubMed Central  Google Scholar 

  6. •• Dass K, Petrusan AJ, Beaumont J, Zee P, Lai J-S, Fishbein A. Assessment of sleep disturbance in children with allergic rhinitis. Ann Allergy, Asthma Immunol. 2017;118(4):505–6. https://doi.org/10.1016/j.anai.2016.12.022. This article provides an important assessment of sleep disorders in patients with allergic rhinitis

    Article  Google Scholar 

  7. Meltzer EO, Farrar JR, Sennett C. Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients. J Allergy Clin Immunol Pract. 2017;5(3):779–789.e6. https://doi.org/10.1016/j.jaip.2016.10.010.

    Article  PubMed  Google Scholar 

  8. Gunawan F, Hui JW, Mehta A, et al. Significant cognitive function impairment in association with sleep disruption in patients with chronic rhinosinusitis (CRS). J Allergy Clin Immunol. 2017;139(2):AB66. https://doi.org/10.1016/j.jaci.2016.12.263.

    Article  Google Scholar 

  9. Demoly P, Maigret P, Elias Billon I, Allaert F-A. Allergic rhinitis increases the risk of driving accidents. J Allergy Clin Immunol. 2017;140(2):614–6. https://doi.org/10.1016/j.jaci.2017.01.037.

    Article  PubMed  Google Scholar 

  10. Zhou Y, Aris IM, Tan SS, et al. Sleep duration and growth outcomes across the first two years of life in the GUSTO study. Sleep Med. 2015;16:1281–6. https://doi.org/10.1016/j.sleep.2015.07.006.

    Article  PubMed  Google Scholar 

  11. Trikojat K, Luksch H, Rösen-Wolff A, Plessow F, Schmitt J, Buske-Kirschbaum A. “Allergic mood”—depressive and anxiety symptoms in patients with seasonal allergic rhinitis (SAR) and their association to inflammatory, endocrine, and allergic markers. 2017. doi:https://doi.org/10.1016/j.bbi.2017.05.005.

  12. Soler ZM, Hyer JM, Rudmik L, Ramakrishnan V, Smith TL, Schlosser RJ. Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis. J Allergy Clin Immunol. 2016;137(4):1054–62. https://doi.org/10.1016/j.jaci.2015.11.019.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sakano E, Sarinho ES, Cruz AA, et al. IV Brazilian Consensus on Rhinitis—an update on allergic rhinitis. Braz J Otorhinolaryngol. 2017; https://doi.org/10.1016/j.bjorl.2017.10.006.

  14. Chen J-R, Jin L, Li X-Y. The effectiveness of nasal saline irrigation (seawater) in treatment of allergic rhinitis in children. Int J Pediatr Otorhinolaryngol. 2014;78(7):1115–8. https://doi.org/10.1016/j.ijporl.2014.04.026.

    Article  PubMed  Google Scholar 

  15. Bartle J. Patient education in the effective management of hay fever. Nurs Stand. 2016;30(43):48–53. https://doi.org/10.7748/ns.2016.e9220.

    Article  PubMed  Google Scholar 

  16. Bérard A, Sheehy O, Kurzinger M-L, Juhaeri J. Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. J Allergy Clin Immunol. 2016;138(1):97–104.e7. https://doi.org/10.1016/j.jaci.2016.01.021.

    Article  PubMed  CAS  Google Scholar 

  17. Namazy JA, Schatz M, Jolla L, Diego S. The safety of intranasal steroids during pregnancy: a good start. J Allergy Clin Immunol. 2016;138:105–6. https://doi.org/10.1016/j.jaci.2016.04.026.

    Article  PubMed  Google Scholar 

  18. FDA. Flonase Allergy Relief approval letter dated July 23, 2014. FDA website. www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205434Orig1s000ltr.pdf.

  19. FDA. Nasacort Allergy 24HR approval letter dated October 11, 2013. FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020468Orig1s035ltr.pdf. Accessed 20 Oct 2017.

  20. FDA. Rhinocort Allergy Spray approval letter dated May 22, 2017. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/020746Orig1s037ltr.pdf. Accessed 20 Oct 2017.

  21. Mortuaire G, Michel J, Papon JF, et al. Specific immunotherapy in allergic rhinitis. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134:253–8. https://doi.org/10.1016/j.anorl.2017.06.005.

    Article  PubMed  CAS  Google Scholar 

  22. Berings M, Karaaslan C, Altunbulakli C, et al. Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. 2017. doi:https://doi.org/10.1016/j.jaci.2017.08.025.

  23. Epstein TG, Calabria C, Cox LS, Dreborg S. Current evidence on safety and practical considerations for administration of sublingual allergen immunotherapy (SLIT) in the United States. J Allergy Clin Immunol Pract. 2017;5(1):34–40.e2. https://doi.org/10.1016/J.JAIP.2016.09.017.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oakland University William Beaumont School of Medicine, Rochester, MI, USA

    Quoc Tuan Ngo BSc & Kathleen Dass MD

  2. Department of Internal Medicine – Allergy Immunology, Beaumont Health System, Royal Oak, MI, USA

    Kathleen Dass MD

Authors
  1. Quoc Tuan Ngo BSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen Dass MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen Dass MD.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

With regard to the authors’ research cited in this paper, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. In addition, all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Additional information

This article is part of the Topical Collection on Allergic Rhinitis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ngo, Q.T., Dass, K. Impact and Assessment of Sleep Disturbance in Adults and Children with Allergic Rhinitis. Curr Treat Options Allergy 5, 236–246 (2018). https://doi.org/10.1007/s40521-018-0163-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40521-018-0163-7

Keywords

Search

Navigation